Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Chee Gee See, Jeffrey Bishop, Linda Greub

Premium

Proteome Sciences said this week it had appointed Chee Gee See director of personalized medicine.

Previously Gee See was a biomarker and experimental medicine leader at Roche. Before that he was an analyst at GlaxoSmithKline.


Singulex said this week that it has appointed Jeffrey Bishop vice president, research and development and Linda Greub vice president, business development.

Bishop was previously vice president, research and development at Alere.

Greub was previously global director of strategy, business development at Novartis. Prior to that she was senior director, strategy and business development at Applied Biosystems as well as a senior healthcare analyst for several investment banks and hedge funds.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.